Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
for
Renal Cell Carcinoma (RCC),
Location: Boston MA, New Haven CT, New York NY, Hackensack NJ,
Sponsor: Exelixis
Sex: All
Age: 18+
Code: NCT05176483
Phase1, Recruiting
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
for
Relapsed/Refractory Small Cell Lung Cancer
Location: Durham NC, Buffalo NY, Cleveland OH, Detroit MI,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT07325136
Phase1, Phase2, Recruiting
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
for
Castration-Resistant Prostate Carcinoma,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT04693377
Recruiting
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
for
Small Cell Lung Cancer (SCLC)
Location: Boston MA, Charlottesville VA, Chicago IL
Sponsor: Alliance Foundation Trials, LLC.
Sex: All
Age: 18+
Code: NCT07149363
Phase2, Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
for
Metastatic Castration Resistant Prostate Cancer (mCRPC),
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
for
Non-small Cell Lung Cancer
Location: Rochester NY
Sponsor: University of Rochester
Sex: All
Age: 18+
Code: NCT04297605
Phase1, Recruiting
Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC
for
Non Small Cell Lung Cancer, Stage III Lung Cancer
Location: Montreal
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Sex: All
Age: 18+
Code: NCT06878274
Phase2, Recruiting
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications